PD 166326 is a pyridopyrimidine-type inhibitor of receptor tyrosine kinases that inhibits c-abl （IC50 = 8 nM） and Bcr/Abl-dependent cell growth （IC50 = 0.4 nM）. In addition to targeting a select group of receptor tyrosine kinases， PD 166326 also potently inhibits c-src （IC50 = 6 nM）. Orally administered PD 166326 is well tolerated and effectively blocks Bcr/Abl kinase activity in vivo. Moreover， PD 166326 affects a distinct set of kinases from those targeted by imatinib mesylate （STI571） and can reduce the growth of some imatinib-resistant cells both in vitro and in vivo in animal models of chronic myelogenous leukemia.
产品描述
A pyridopyrimidine-type inhibitor of receptor tyrosine kinases that inhibits c-abl （IC50 = 8 nM） and Bcr/Abl-dependent cell growth （IC50 = 0.4 nM）； also potently inhibits c-src （IC50 = 6 nM）； effectively blocks Bcr/Abl kinase activity in vivo
